A genetic syndrome that affects bones
Osteogenesis Imperfecta (OI) is a hereditary disorder occurring in 1:10,000 births and characterised by osteopenia (bone loss) and skeletal fragility (fractures). Secondary features include short stature, skeletal deformities, blue sclera and dentinogenesis imperfect. (1) There is a large clinical variability in OI, and severity ranges from mild to lethal, based on radiological characteristics. Genetically, OI is a collagen-related syndrome. Type I collagen is a heterotrimeric helical structure synthesized by bone-forming cells (osteoblasts), and it constitutes the most abundant protein of the skeletal organic matrix. (2) Synthesis of type I collagen is a complex process. (3) Collagen molecules are cross-linked into fibrils (which confer tensile strength to the bones). Those are then mineralised by hydroxy-apatites (which provides compressive strength) and assembled into fibres.
Dominant mutations in either the COL1A1 or the COLA1A2 genes are responsible for up to 90% of all OI cases. These mutations (more than 1,000 of which have been identified) lead to impairment of collagen structure and production, which in either quantitative or qualitative bone extracellular matrix (ECM) defects. Mutations affecting ECM structure have serious health consequences because the skeleton protects visceral organs and the central nervous system and provides structural support. Bones also store fat in the yellow bone marrow found within the medullary cavity, whilst the red marrow located at the end of long bones is the site of haematopoiesis. In addition, the ECM constitutes a reservoir of phosphate, calcium, and growth factors, and is involved in trapping dangerous molecules.
Stem cell therapy for OI aims to improve bone quality by harnessing the ability of mesenchymal stem cells (MSC) to differentiate into osteoblasts, with the rationale that donor cells would engraft into bones, produce normal collagen and function as a cell replacement. Stem cells have, therefore, been proposed for the treatment of OI (4) and, in particular, prenatal foetal stem cell therapy (foetal stem cells injected into a foetus, i.e. foetal-to-foetal) approach, which offers a promising route to effective treatment. (5) Human foetal stem cells are more primitive than stem cells isolated from adult tissues and present advantageous characteristics compared to their adult counterparts, i.e. they possess a higher level of plasticity, differentiate more readily into specific lineages, grow faster, senesce later, express higher levels of adhesion molecules, and are smaller in size. (6,7) Prenatal cell therapy capitalises on the small size of the foetus and its immunological naivete. In addition, stem cells delivered in utero benefit from the expansion of endogenous stem cells and may prevent organ injury before irreversible damage. (8)
However, human foetal stem cells used are isolated from either foetal blood drawn by cardiac puncture, either during termination of pregnancy or during ongoing pregnancy, albeit using an invasive procedure associated with a high risk of morbidity and mortality for both the foetus and the mother (9). Foetal cells can also be isolated from the first-trimester liver (following termination of pregnancy) and such cells are currently used in The Boost Brittle Bones Before Birth (BOOSTB4) clinical trial, which aims to investigate the safety and efficacy of transplanting foetal derived MSCs prenatally and/or in early postnatal life to treat severe Osteogenesis Imperfecta (OI) (10). Alternatively, foetal stem cells can be isolated during ongoing pregnancy from the amniotic fluid, either during mid-trimester amniocentesis or at birth (11,12) or from the chorionic villi of the placenta during first-trimester chorionic villi sampling (13).
We have demonstrated that human fetal stem cells isolated from first trimester blood possess superior osteogenic differentiation potential compared to adult stem cells isolated from bone marrow and to fetal stem cells isolated from first trimester liver. We showed that in utero transplantation of these cells in an experimental model of severe OI resulted in a drastic 75% decrease in fracture rate incidence and skeletal brittleness, and improvement of bone strength and quality.(14) A similar outcome was obtained using placenta-derived foetal stem cells (15) and amniotic fluid stem cells following perinatal transplantation into experimental models. (16,17)
Understanding the mechanisms of action of donor cells will enable the engineering of donor cells with superior efficacy to stimulate bone formation and strengthen the skeleton. Despite their potential to differentiate down the osteogenic lineage, there is little evidence that donor cells contribute to regenerating bones through direct differentiation, due to the very low level of donor cell engraftment reported in all our studies. When placed in an osteogenic microenvironment in vitro, foetal stem cells readily differentiate into osteoblasts and produce wild type collagen molecules. However, there are insufficient proofs that collagen molecules of donor cell origin contribute to the formation of the host bone ECM to confer superior resistance to fracture.
It is now well accepted that stem cells can influence the behaviour of target cells through the release of paracrine factors and, therefore, contribute to tissue regeneration indirectly. We have indeed recently shown that donor stem cells stimulate the differentiation of resident osteoblasts, which were unable to fully mature in the absence of stem cell treatment. (16,17) We are now focusing our efforts on understanding the precise molecular mechanisms by which donor cells improve skeletal health to counteract bone fragility caused by various OI-causative mutations.
References
Please note: This is a commercial profile
2019. This work is licensed under aCC BY 4.0 license.
More:
Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope - Open Access Government
- Cardiac Regeneration - Center for Regenerative Medicine - Mayo Clinic ... - April 11th, 2018 [April 11th, 2018]
- Cardiac Regeneration - Mayo Clinic - April 22nd, 2018 [April 22nd, 2018]
- Materials - MDPI - May 18th, 2018 [May 18th, 2018]
- Cardiac Stem Cell Research - Cedars-Sinai - May 22nd, 2018 [May 22nd, 2018]
- Cardiac regeneration: current therapiesfuture concepts ... - May 26th, 2018 [May 26th, 2018]
- Cardiac Regeneration - Victor Chang Cardiac Research Institute - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardio 2018 Events | Cardiac ... - June 6th, 2018 [June 6th, 2018]
- Laboratory for Cardiac Regeneration | Baylor College of ... - June 18th, 2018 [June 18th, 2018]
- Regeneration of Muscle - July 8th, 2018 [July 8th, 2018]
- Regeneration of Muscle - eLS: Essential for Life Science - July 14th, 2018 [July 14th, 2018]
- Cardiac Repair and Regeneration Research Unit | Heart and ... - July 25th, 2018 [July 25th, 2018]
- Myogenesis - Wikipedia - August 8th, 2018 [August 8th, 2018]
- Regeneration (biology) - Wikipedia - August 21st, 2018 [August 21st, 2018]
- World Cardiology and Cardiologist Meeting - August 21st, 2018 [August 21st, 2018]
- Cardiac (comics) - Wikipedia - August 26th, 2018 [August 26th, 2018]
- Cardiac regeneration and repair - 1st Edition - Elsevier - September 21st, 2018 [September 21st, 2018]
- Post-doc position available cardiac regeneration ... - September 29th, 2018 [September 29th, 2018]
- UW Bioengineering: Building World Leadership in Heart ... - September 29th, 2018 [September 29th, 2018]
- Cardiac Regeneration - What Science Can Do - AstraZeneca - October 2nd, 2018 [October 2nd, 2018]
- Cardiac Regeneration, Stem Cells | Research | Baylor ... - November 30th, 2018 [November 30th, 2018]
- Cardiac Regeneration - Victor Chang Institute - December 6th, 2018 [December 6th, 2018]
- Entering a new era in vascular and cardiac regeneration ... - December 19th, 2018 [December 19th, 2018]
- Cardiac regeneration and repair - 1st Edition - December 19th, 2018 [December 19th, 2018]
- Heart Regeneration Technologies - December 19th, 2018 [December 19th, 2018]
- Cardiac Regeneration - Center for Regenerative Medicine ... - December 19th, 2018 [December 19th, 2018]
- Zebrafish Heart Regeneration | HHMI BioInteractive - December 22nd, 2018 [December 22nd, 2018]
- Rapid cell regeneration - Heroes Wiki - December 22nd, 2018 [December 22nd, 2018]
- Cardiac muscle - Wikipedia - December 23rd, 2018 [December 23rd, 2018]
- Cardiac regeneration in and : discrepancies and problems ... - January 8th, 2019 [January 8th, 2019]
- OHSU Center for Regenerative Medicine Heart Regeneration ... - January 8th, 2019 [January 8th, 2019]
- Dr. Sanjiv Dhingra, Cardiac Regeneration and Tissue ... - January 30th, 2019 [January 30th, 2019]
- Mending a Broken Heart: Stem Cells and Cardiac Repair ... - February 20th, 2019 [February 20th, 2019]
- Cardiac Repair and Regeneration | Division of Cardiology ... - February 20th, 2019 [February 20th, 2019]
- Stem Cell Therapy and Stem Cell Injection Provider Finder ... - March 5th, 2019 [March 5th, 2019]
- KearnsSayre syndrome - Wikipedia - March 8th, 2019 [March 8th, 2019]
- Ruohola-Baker Lab - March 15th, 2019 [March 15th, 2019]
- MTS Science - May 3rd, 2019 [May 3rd, 2019]
- New Insights Into the Healing Capacity of the Heart: The Hippo Pathway - Cath Lab Digest - September 26th, 2019 [September 26th, 2019]
- Conjugated polymers optically regulate the fate of endothelial colony-forming cells - Science Advances - September 29th, 2019 [September 29th, 2019]
- The nanoengineer working to mend broken hearts - UNSW Newsroom - September 29th, 2019 [September 29th, 2019]
- New insights into heart's healing capacity - Baylor College of Medicine News - September 29th, 2019 [September 29th, 2019]
- Tenaya Therapeutics Closes $92 Million Series B Financing - BioSpace - October 5th, 2019 [October 5th, 2019]
- Regenerative medicine today: Are diabetes and vascular disease treatments ready for the clinic? - Science Magazine - October 5th, 2019 [October 5th, 2019]
- Reviewing resTORbio Inc. (TORC)'s and Anika Therapeutics Inc. (NASDAQ:ANIK)'s results - MS Wkly - October 14th, 2019 [October 14th, 2019]
- TAMassociati: the new Church of the Resurrection in Varignano - Floornature.com - October 14th, 2019 [October 14th, 2019]
- What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News - October 19th, 2019 [October 19th, 2019]
- Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 24th, 2019 [October 24th, 2019]
- Ottawa-based treatment a leap forward in addressing heart failure - Winnipeg Sun - October 27th, 2019 [October 27th, 2019]
- Global Regenerative Medicines Market Demand Analysis & Opportunity Evaluation Report 2019-2027 with Focus on U.S. & Europe -... - November 15th, 2019 [November 15th, 2019]
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 15th, 2019 [November 15th, 2019]
- SANUWAVE Health Reports Third Quarter 2019 Financial Results Other OTC:SNWV - GlobeNewswire - November 16th, 2019 [November 16th, 2019]
- Moderna: Undervalued As The Promising Pipeline Awaits Collaborations - Seeking Alpha - November 23rd, 2019 [November 23rd, 2019]
- Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction... - November 23rd, 2019 [November 23rd, 2019]
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - December 5th, 2019 [December 5th, 2019]
- AgeX Therapeutics Issues Year-End Letter to Shareholders - BioSpace - December 9th, 2019 [December 9th, 2019]
- Polymeric Biomaterials Market Trends Analysis Forecast to 2019-2024 |Evolving Industry Overview by Types, Applications, Size & Share - Sino News... - December 16th, 2019 [December 16th, 2019]
- SMD - Researchers look behind the biological curtain on how fish oil might fight inflammatory disease - QMUL - December 16th, 2019 [December 16th, 2019]
- Suspended animation, you say? The biggest and freakiest scientific breakthroughs of 2019 - SYFY WIRE - December 29th, 2019 [December 29th, 2019]
- 2019: Year in Pictures by Robert Cohen | Metro - STLtoday.com - December 31st, 2019 [December 31st, 2019]
- MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology... - January 15th, 2020 [January 15th, 2020]
- Cells that regenerate heart in zebrafish discovered - Biology Reporter - February 7th, 2020 [February 7th, 2020]
- SANUWAVE Health Appoints Dr. Tom Price to Its Board of Directors - Yahoo Finance - February 7th, 2020 [February 7th, 2020]
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Associated Press - March 19th, 2020 [March 19th, 2020]
- Researchers and Doctors alike pursuing the field of stem cell research in treating heart attack survivors - Medical Herald - March 19th, 2020 [March 19th, 2020]
- Artificial Heart Lung Machines Market report reviews opportunities and analysis by size, share, trends, manufacturer, forecast 2020-2026 - WhaTech... - April 29th, 2020 [April 29th, 2020]
- Scientists have figured out how to make the heart to regenerate - The Times Hub - April 29th, 2020 [April 29th, 2020]
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 9th, 2020 [May 9th, 2020]
- SANUWAVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold First Quarter Financial Results and Business Update Call on Monday, May 18, 2020 - Yahoo Finance - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold Investor Live Webcast on Wednesday, June 10, 2020 - Yahoo Finance - June 10th, 2020 [June 10th, 2020]
- SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity's UltraMIST and Exclusive Partnership Rights for Wound Care Biologic... - June 11th, 2020 [June 11th, 2020]
- SANUWAVE Health, Inc. Discusses The Potential of Their Celularity Acquisition with The Stock Day Podcast (SNWV) July 1, 2020 - Stock Day Media - July 1st, 2020 [July 1st, 2020]
- Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire - July 1st, 2020 [July 1st, 2020]
- Growth and demand of Plasma Therapy in the Asia Pacific Region available in the latest report - WhaTech Technology and Markets News - July 4th, 2020 [July 4th, 2020]
- Plasma Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line - August 14th, 2020 [August 14th, 2020]
- Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen for Vascular Repair - BioSpace - August 14th, 2020 [August 14th, 2020]
- Polymeric Biomaterials Market Insights by Current Trends 2020 Future Demand by Top Key Players, Regions, Industry Size, and Business Strategy... - September 11th, 2020 [September 11th, 2020]
- CORRECTION - SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE From Largest Medicare and Medicaid Administrator in U.S. - Stockhouse - September 11th, 2020 [September 11th, 2020]
- New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19 - PRNewswire - September 11th, 2020 [September 11th, 2020]